Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Toward a systems approach to the human cytochrome P450 ensemble: interactions between CYP2D6 and CYP2E1 and their functional consequences.

Davydov DR, Davydova NY, Rodgers JT, Rushmore TH, Jones JP.

Biochem J. 2017 Oct 10;474(20):3523-3542. doi: 10.1042/BCJ20170543.

2.

Discovery of selective glucocorticoid receptor modulator MK-5932.

Bungard CJ, Hartman GD, Manikowski JJ, Perkins JJ, Bai C, Brandish PE, Euler DH, Hershey JC, Schmidt A, Fang Y, Norcross RT, Rushmore TH, Thompson CD, Meissner RS.

Bioorg Med Chem. 2011 Dec 15;19(24):7374-86. doi: 10.1016/j.bmc.2011.10.054. Epub 2011 Oct 24.

PMID:
22079253
3.

Cytotoxicity of 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione (DCPT) and analogues in wild type and CYP3A4 stably transfected HepG2 cells.

Frederick DM, Jacinto EY, Patel NN, Rushmore TH, Tchao R, Harvison PJ.

Toxicol In Vitro. 2011 Dec;25(8):2113-9. doi: 10.1016/j.tiv.2011.09.015. Epub 2011 Sep 22.

4.

Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver.

Yang X, Zhang B, Molony C, Chudin E, Hao K, Zhu J, Gaedigk A, Suver C, Zhong H, Leeder JS, Guengerich FP, Strom SC, Schuetz E, Rushmore TH, Ulrich RG, Slatter JG, Schadt EE, Kasarskis A, Lum PY.

Genome Res. 2010 Aug;20(8):1020-36. doi: 10.1101/gr.103341.109. Epub 2010 Jun 10.

5.

Mapping the genetic architecture of gene expression in human liver.

Schadt EE, Molony C, Chudin E, Hao K, Yang X, Lum PY, Kasarskis A, Zhang B, Wang S, Suver C, Zhu J, Millstein J, Sieberts S, Lamb J, GuhaThakurta D, Derry J, Storey JD, Avila-Campillo I, Kruger MJ, Johnson JM, Rohl CA, van Nas A, Mehrabian M, Drake TA, Lusis AJ, Smith RC, Guengerich FP, Strom SC, Schuetz E, Rushmore TH, Ulrich R.

PLoS Biol. 2008 May 6;6(5):e107. doi: 10.1371/journal.pbio.0060107.

6.

Diclofenac hydroxylation in monkeys: efficiency, regioselectivity, and response to inhibitors.

Tang C, Fang Y, Booth-Genthe C, Kuo Y, Kuduk SD, Rushmore TH, Carr BA.

Biochem Pharmacol. 2007 Mar 15;73(6):880-90. Epub 2006 Nov 25.

PMID:
17223083
7.

Compendium of gene expression profiles comprising a baseline model of the human liver drug metabolism transcriptome.

Slatter JG, Templeton IE, Castle JC, Kulkarni A, Rushmore TH, Richards K, He Y, Dai X, Cheng OJ, Caguyong M, Ulrich RG.

Xenobiotica. 2006 Oct-Nov;36(10-11):938-62.

PMID:
17118915
8.

Lack of effect of aprepitant on hydrodolasetron pharmacokinetics in CYP2D6 extensive and poor metabolizers.

Li SX, Pequignot E, Panebianco D, Lupinacci P, Majumdar A, Rosen L, Ahmed T, Royalty JE, Rushmore TH, Murphy MG, Petty KJ.

J Clin Pharmacol. 2006 Jul;46(7):792-801.

PMID:
16809805
9.

Development and characterization of LLC-PK1 cells containing Sprague-Dawley rat Abcb1a (Mdr1a): comparison of rat P-glycoprotein transport to human and mouse.

Booth-Genthe CL, Louie SW, Carlini EJ, Li B, Leake BF, Eisenhandler R, Hochman JH, Mei Q, Kim RB, Rushmore TH, Yamazaki M.

J Pharmacol Toxicol Methods. 2006 Jul-Aug;54(1):78-89. Epub 2006 Mar 20.

PMID:
16545584
10.

Induction of CYP1A in the beagle dog by an inhibitor of kinase insert domain-containing receptor: differential effects in vitro and in vivo on mRNA and functional activity.

Gibson CR, Lin C, Singh R, Brown CM, Richards K, Brunner J, Michel K, Adelsberger J, Carlini E, Boothe-Genthe C, Raab C, Luu M, Michael A, Parikh M, Ciecko P, Subramanian R, Krolikowski P, Rodrigues AD, Baillie TA, Rushmore TH.

Drug Metab Dispos. 2005 Jul;33(7):1044-51. Epub 2005 Apr 15.

PMID:
15833927
11.

Selective inhibition of dog hepatic CYP2B11 and CYP3A12.

Lu P, Singh SB, Carr BA, Fang Y, Xiang CD, Rushmore TH, Rodrigues AD, Shou M.

J Pharmacol Exp Ther. 2005 May;313(2):518-28. Epub 2005 Jan 26.

PMID:
15677349
12.

Sulfotransferase 1E1 is a low km isoform mediating the 3-O-sulfation of ethinyl estradiol.

Schrag ML, Cui D, Rushmore TH, Shou M, Ma B, Rodrigues AD.

Drug Metab Dispos. 2004 Nov;32(11):1299-303.

PMID:
15483196
13.

Effect of quinidine on the 10-hydroxylation of R-warfarin: species differences and clearance projection.

Chen Q, Tan E, Strauss JR, Zhang Z, Fenyk-Melody JE, Booth-Genthe C, Rushmore TH, Stearns RA, Evans DC, Baillie TA, Tang W.

J Pharmacol Exp Ther. 2004 Oct;311(1):307-14. Epub 2004 May 26.

PMID:
15163679
14.

Activators of the rat pregnane X receptor differentially modulate hepatic and intestinal gene expression.

Hartley DP, Dai X, He YD, Carlini EJ, Wang B, Huskey SE, Ulrich RG, Rushmore TH, Evers R, Evans DC.

Mol Pharmacol. 2004 May;65(5):1159-71.

PMID:
15102944
15.

Stereo- and regioselectivity account for the diversity of dehydroepiandrosterone (DHEA) metabolites produced by liver microsomal cytochromes P450.

Miller KK, Cai J, Ripp SL, Pierce WM Jr, Rushmore TH, Prough RA.

Drug Metab Dispos. 2004 Mar;32(3):305-13.

PMID:
14977864
16.

Substrate specificity and kinetic properties of seven heterologously expressed dog cytochromes p450.

Shou M, Norcross R, Sandig G, Lu P, Li Y, Lin Y, Mei Q, Rodrigues AD, Rushmore TH.

Drug Metab Dispos. 2003 Sep;31(9):1161-9.

PMID:
12920172
17.

Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes.

Rushmore TH, Kong AN.

Curr Drug Metab. 2002 Oct;3(5):481-90. Review.

PMID:
12369894
18.

Cytochrome P450 pharmacogenetics in drug development: in vitro studies and clinical consequences.

Rodrigues AD, Rushmore TH.

Curr Drug Metab. 2002 Jun;3(3):289-309. Review. Erratum in: Curr Drug Metab. 2002 Oct;3(5):559..

PMID:
12083322
19.

Inhibition kinetics of monoclonal antibodies against cytochromes P450.

Mei Q, Tang C, Lin Y, Rushmore TH, Shou M.

Drug Metab Dispos. 2002 Jun;30(6):701-8.

PMID:
12019198
20.

Testosterone, 7-benzyloxyquinoline, and 7-benzyloxy-4-trifluoromethyl-coumarin bind to different domains within the active site of cytochrome P450 3A4.

Lu P, Lin Y, Rodrigues AD, Rushmore TH, Baillie TA, Shou M.

Drug Metab Dispos. 2001 Nov;29(11):1473-9.

PMID:
11602524
21.

Enzyme kinetics of cytochrome P450-mediated reactions.

Shou M, Lin Y, Lu P, Tang C, Mei Q, Cui D, Tang W, Ngui JS, Lin CC, Singh R, Wong BK, Yergey JA, Lin JH, Pearson PG, Baillie TA, Rodrigues AD, Rushmore TH.

Curr Drug Metab. 2001 Mar;2(1):17-36. Review.

PMID:
11465149
22.

An invasive cleavage assay for direct quantitation of specific RNAs.

Eis PS, Olson MC, Takova T, Curtis ML, Olson SM, Vener TI, Ip HS, Vedvik KL, Bartholomay CT, Allawi HT, Ma WP, Hall JG, Morin MD, Rushmore TH, Lyamichev VI, Kwiatkowski RW.

Nat Biotechnol. 2001 Jul;19(7):673-6. Erratum in: Nat Biotechnol 2002 Mar;20(3):307.

PMID:
11433281
23.

In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics.

Tang C, Shou M, Rushmore TH, Mei Q, Sandhu P, Woolf EJ, Rose MJ, Gelmann A, Greenberg HE, De Lepeleire I, Van Hecken A, De Schepper PJ, Ebel DL, Schwartz JI, Rodrigues AD.

Pharmacogenetics. 2001 Apr;11(3):223-35.

PMID:
11337938
24.

Halothane-induced liver injury in outbred guinea pigs: role of trifluoroacetylated protein adducts in animal susceptibility.

Bourdi M, Amouzadeh HR, Rushmore TH, Martin JL, Pohl LR.

Chem Res Toxicol. 2001 Apr;14(4):362-70.

PMID:
11304124
25.

Substrate inhibition kinetics for cytochrome P450-catalyzed reactions.

Lin Y, Lu P, Tang C, Mei Q, Sandig G, Rodrigues AD, Rushmore TH, Shou M.

Drug Metab Dispos. 2001 Apr;29(4 Pt 1):368-74.

PMID:
11259318
26.

A kinetic model for the metabolic interaction of two substrates at the active site of cytochrome P450 3A4.

Shou M, Dai R, Cui D, Korzekwa KR, Baillie TA, Rushmore TH.

J Biol Chem. 2001 Jan 19;276(3):2256-62. Epub 2000 Oct 27.

27.

Bioreactor systems in drug metabolism: synthesis of cytochrome P450-generated metabolites.

Rushmore TH, Reider PJ, Slaughter D, Assang C, Shou M.

Metab Eng. 2000 Apr;2(2):115-25.

PMID:
10935727
28.

Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor.

Tang C, Shou M, Mei Q, Rushmore TH, Rodrigues AD.

J Pharmacol Exp Ther. 2000 May;293(2):453-9.

PMID:
10773015
29.

Mechanism-based inactivation of cytochrome P450 3A4 by L-754,394.

Lightning LK, Jones JP, Friedberg T, Pritchard MP, Shou M, Rushmore TH, Trager WF.

Biochemistry. 2000 Apr 18;39(15):4276-87.

PMID:
10757976
30.

Role of a potent inhibitory monoclonal antibody to cytochrome P-450 3A4 in assessment of human drug metabolism.

Mei Q, Tang C, Assang C, Lin Y, Slaughter D, Rodrigues AD, Baillie TA, Rushmore TH, Shou M.

J Pharmacol Exp Ther. 1999 Nov;291(2):749-59.

PMID:
10525096
31.
32.

Studies on cytochrome P-450-mediated bioactivation of diclofenac in rats and in human hepatocytes: identification of glutathione conjugated metabolites.

Tang W, Stearns RA, Bandiera SM, Zhang Y, Raab C, Braun MP, Dean DC, Pang J, Leung KH, Doss GA, Strauss JR, Kwei GY, Rushmore TH, Chiu SH, Baillie TA.

Drug Metab Dispos. 1999 Mar;27(3):365-72.

PMID:
10064567
33.

Electrospray ionization mass spectrometric analysis of intact cytochrome P450: identification of tienilic acid adducts to P450 2C9.

Koenigs LL, Peter RM, Hunter AP, Haining RL, Rettie AE, Friedberg T, Pritchard MP, Shou M, Rushmore TH, Trager WF.

Biochemistry. 1999 Feb 23;38(8):2312-9.

PMID:
10029524
34.
35.

Genetic association between sensitivity to warfarin and expression of CYP2C9*3.

Steward DJ, Haining RL, Henne KR, Davis G, Rushmore TH, Trager WF, Rettie AE.

Pharmacogenetics. 1997 Oct;7(5):361-7.

PMID:
9352571
36.

Transcription regulation of rat glutathione S-transferase Ya subunit gene expression by chemopreventive agents.

Fei P, Matwyshyn GA, Rushmore TH, Kong AN.

Pharm Res. 1996 Jul;13(7):1043-8.

PMID:
8842042
37.

Human prostanoid receptors: cloning and characterization.

Abramovitz M, Adam M, Boie Y, Grygorczyk R, Rushmore TH, Nguyen T, Funk CD, Bastien L, Sawyer N, Rochette C, et al.

Adv Prostaglandin Thromboxane Leukot Res. 1995;23:499-504. No abstract available.

PMID:
7732897
38.

Increased cosedimentation of cytosolic glutathione S-transferases with microsomal fractions prepared from frozen rat liver.

Cribb AE, Griffin GP, Spielberg SP, Rushmore TH, Chauret N, Nicoll-Griffith DA.

Drug Metab Dispos. 1994 Nov-Dec;22(6):969-72. No abstract available.

PMID:
7895617
40.

Cloning and expression of a cDNA for the human prostanoid IP receptor.

Boie Y, Rushmore TH, Darmon-Goodwin A, Grygorczyk R, Slipetz DM, Metters KM, Abramovitz M.

J Biol Chem. 1994 Apr 22;269(16):12173-8.

41.

Cloning and expression of three isoforms of the human EP3 prostanoid receptor.

Adam M, Boie Y, Rushmore TH, Müller G, Bastien L, McKee KT, Metters KM, Abramovitz M.

FEBS Lett. 1994 Jan 31;338(2):170-4.

42.

Cloning and expression of a cDNA for the human prostanoid FP receptor.

Abramovitz M, Boie Y, Nguyen T, Rushmore TH, Bayne MA, Metters KM, Slipetz DM, Grygorczyk R.

J Biol Chem. 1994 Jan 28;269(4):2632-6.

43.

Glutathione S-transferases, structure, regulation, and therapeutic implications.

Rushmore TH, Pickett CB.

J Biol Chem. 1993 Jun 5;268(16):11475-8. Review. No abstract available.

44.

Enantioselective activation of the peroxisome proliferator-activated receptor.

Boie Y, Adam M, Rushmore TH, Kennedy BP.

J Biol Chem. 1993 Mar 15;268(8):5530-4.

46.

Xenobiotic responsive elements controlling inducible expression by planar aromatic compounds and phenolic antioxidants.

Rushmore TH, Pickett CB.

Methods Enzymol. 1991;206:409-20. No abstract available.

PMID:
1784226
47.

Protective activity of different hepatic cytosolic glutathione S-transferases against DNA-binding metabolites of aflatoxin B1.

Quinn BA, Crane TL, Kocal TE, Best SJ, Cameron RG, Rushmore TH, Farber E, Hayes MA.

Toxicol Appl Pharmacol. 1990 Sep 15;105(3):351-63.

PMID:
2173169
49.

Pathogenesis of skin and liver neoplasms in white suckers from industrially polluted areas in Lake Ontario.

Hayes MA, Smith IR, Rushmore TH, Crane TL, Thorn C, Kocal TE, Ferguson HW.

Sci Total Environ. 1990 May 1;94(1-2):105-23.

PMID:
2360036

Supplemental Content

Loading ...
Support Center